Literature DB >> 17893675

A refined method for molecular typing reveals that co-occurrence of PrP(Sc) types in Creutzfeldt-Jakob disease is not the rule.

Silvio Notari1, Sabina Capellari, Jan Langeveld, Armin Giese, Rosaria Strammiello, Pierluigi Gambetti, Hans A Kretzschmar, Piero Parchi.   

Abstract

Molecular typing in Creutzfeldt-Jakob disease (CJD) relies on the detection of distinct protease-resistant prion protein (PrP(Sc)) core fragments, which differ in molecular mass or glycoform ratio. However, the definition and correct identification of CJD cases with a co-occurrence of PrP(Sc) types remains a challenge. With antibodies recognizing a linear epitope in the octapeptide repeat PrP region, supposed to distinguish between the two major PrP(Sc) isoforms (ie, types 1 and 2), it was recently shown that all type 2 cases display an associated band with a type 1 migration pattern, which led to the conclusion that multiple PrP(Sc) types regularly coexist in CJD. We studied brain samples from 53 sporadic CJD and 4 variant CJD subjects using a high-resolution electrophoresis, a wide range of proteinase K (PK) activities, the 'type 1-selective' antibody 12B2, and several unselective antibodies. We found that the type 1-like band detected by 12B2 in all CJD subtypes associated with PrP(Sc) type 2 is not a PK-resistant PrP(Sc) core but rather matches the physicochemical properties of partially cleaved fragments, which result from the several PK cleavage sites included in the N-terminal portion of PrP(Sc). Furthermore, using gels with high resolution and a relatively high PK activity, we were able to increase the detection sensitivity of either type 1 or 2, when coexisting, to amount corresponding to 3-5% of the total PrP(Sc) signal (ie, weak band of one type/total PrP(Sc)). Our results show that there are many pitfalls associated with the use of 'type 1 selective' antibodies for CJD typing studies and that co-occurrence of PrP(Sc) types in CJD is not the rule. The present results further validate the rationale basis of current CJD classification and the qualitative nature of molecular typing in CJD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893675     DOI: 10.1038/labinvest.3700676

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  30 in total

1.  Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease.

Authors:  Piero Parchi; Maura Cescatti; Silvio Notari; Walter J Schulz-Schaeffer; Sabina Capellari; Armin Giese; Wen-Quan Zou; Hans Kretzschmar; Bernardino Ghetti; Paul Brown
Journal:  Brain       Date:  2010-09-07       Impact factor: 13.501

2.  Characterization of truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease.

Authors:  Silvio Notari; Rosaria Strammiello; Sabina Capellari; Armin Giese; Maura Cescatti; Jacques Grassi; Bernardino Ghetti; Jan P M Langeveld; Wen-Quan Zou; Pierluigi Gambetti; Hans A Kretzschmar; Piero Parchi
Journal:  J Biol Chem       Date:  2008-08-27       Impact factor: 5.157

3.  Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics.

Authors:  Ignazio Cali; Rudolph Castellani; Amer Alshekhlee; Yvonne Cohen; Janis Blevins; Jue Yuan; Jan P M Langeveld; Piero Parchi; Jiri G Safar; Wen-Quan Zou; Pierluigi Gambetti
Journal:  Brain       Date:  2009-09-04       Impact factor: 13.501

4.  Incongruity between Prion Conversion and Incubation Period following Coinfection.

Authors:  Katie A Langenfeld; Ronald A Shikiya; Anthony E Kincaid; Jason C Bartz
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

Review 5.  Molecular biology and pathology of prion strains in sporadic human prion diseases.

Authors:  Pierluigi Gambetti; Ignazio Cali; Silvio Notari; Qingzhong Kong; Wen-Quan Zou; Witold K Surewicz
Journal:  Acta Neuropathol       Date:  2010-11-07       Impact factor: 17.088

6.  Co-occurrence of types 1 and 2 PrP(res) in sporadic Creutzfeldt-Jakob disease MM1.

Authors:  Atsushi Kobayashi; Kenta Mizukoshi; Yasushi Iwasaki; Hajime Miyata; Yasuji Yoshida; Tetsuyuki Kitamoto
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

7.  Experimental verification of a traceback phenomenon in prion infection.

Authors:  Atsushi Kobayashi; Nobuyuki Sakuma; Yuichi Matsuura; Shirou Mohri; Adriano Aguzzi; Tetsuyuki Kitamoto
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  The octarepeat region of the prion protein is conformationally altered in PrP(Sc).

Authors:  Alice Y Yam; Carol Man Gao; Xuemei Wang; Ping Wu; David Peretz
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

9.  Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification.

Authors:  Piero Parchi; Rosaria Strammiello; Silvio Notari; Armin Giese; Jan P M Langeveld; Anna Ladogana; Inga Zerr; Federico Roncaroli; Patrich Cras; Bernardino Ghetti; Maurizio Pocchiari; Hans Kretzschmar; Sabina Capellari
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088

10.  Multiorgan detection and characterization of protease-resistant prion protein in a case of variant CJD examined in the United States.

Authors:  Silvio Notari; Francisco J Moleres; Stephen B Hunter; Ermias D Belay; Lawrence B Schonberger; Ignazio Cali; Piero Parchi; Wun-Ju Shieh; Paul Brown; Sherif Zaki; Wen-Quan Zou; Pierluigi Gambetti
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.